BACKGROUND: The HeartMate 3 (HM3) left ventricular assist device (LVAD) (Abbott, Inc, Chicago, Ill) is a fully magnetically levitated centrifugal implantable pump used to treat patients with chronic heart failure. The MOMENTUM (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3) trial demonstrated that patients treated with the HM3 experienced reduced need for reoperation for LVAD replacement compared with a control group receiving an axial flow design, Heartmate II (Abbott, Inc). However, there are few reports of using HM3 as the replacement pump in patients who already are supported by a durable LVAD and experience a device-related complication necessitating replacement. METHODS: An institutional LVAD database was used to identify 19 consecutive patients who underwent pump replacement to HM3 (group 1) versus 85 consecutive control patients who underwent pump replacement to either Heartmate II or HeartWare Ventricular Assist Device (Medtronic Inc, Minneapolis, Minn) (group 2), at a single institution from January 2010 to August 2018. Patient baseline characteristic and outcomes were obtained from a prospectively maintained database. The primary endpoint was a composite of freedom from death or need for another replacement surgery. RESULTS: There was no difference between the groups in heart failure etiology, indication for replacement, as well as the average days on the previous pump or the type of previous pump. The HM3 group did have a significantly greater body mass index (37 vs 31.6 P = .01), a greater number of previous LVAD implants (36.8% vs 5.9%, had 2 previous LVADs, P < .001), and a greater number of previous sternotomies (31.6% vs 7.1%, had 3 previous sternotomies, P = .001). No difference was found between the groups in terms of postoperative adverse event rates. With regards to the primary endpoint, the patients with HM3 replacements (group 1) versus group 2 experienced significantly greater freedom from either death or need for another replacement during the follow-up period (P = .039). During follow-up, there were no thrombosis events for the patients who received replacement with HM3. CONCLUSIONS: LVAD replacement with HM3 can be performed safely and may be considered as the pump of choice in patients requiring LVAD replacement.
BACKGROUND: The HeartMate 3 (HM3) left ventricular assist device (LVAD) (Abbott, Inc, Chicago, Ill) is a fully magnetically levitated centrifugal implantable pump used to treat patients with chronic heart failure. The MOMENTUM (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3) trial demonstrated that patients treated with the HM3 experienced reduced need for reoperation for LVAD replacement compared with a control group receiving an axial flow design, Heartmate II (Abbott, Inc). However, there are few reports of using HM3 as the replacement pump in patients who already are supported by a durable LVAD and experience a device-related complication necessitating replacement. METHODS: An institutional LVAD database was used to identify 19 consecutive patients who underwent pump replacement to HM3 (group 1) versus 85 consecutive control patients who underwent pump replacement to either Heartmate II or HeartWare Ventricular Assist Device (Medtronic Inc, Minneapolis, Minn) (group 2), at a single institution from January 2010 to August 2018. Patient baseline characteristic and outcomes were obtained from a prospectively maintained database. The primary endpoint was a composite of freedom from death or need for another replacement surgery. RESULTS: There was no difference between the groups in heart failure etiology, indication for replacement, as well as the average days on the previous pump or the type of previous pump. The HM3 group did have a significantly greater body mass index (37 vs 31.6 P = .01), a greater number of previous LVAD implants (36.8% vs 5.9%, had 2 previous LVADs, P < .001), and a greater number of previous sternotomies (31.6% vs 7.1%, had 3 previous sternotomies, P = .001). No difference was found between the groups in terms of postoperative adverse event rates. With regards to the primary endpoint, the patients with HM3 replacements (group 1) versus group 2 experienced significantly greater freedom from either death or need for another replacement during the follow-up period (P = .039). During follow-up, there were no thrombosis events for the patients who received replacement with HM3. CONCLUSIONS: LVAD replacement with HM3 can be performed safely and may be considered as the pump of choice in patients requiring LVAD replacement.
Authors: Mandeep R Mehra; Nir Uriel; Yoshifumi Naka; Joseph C Cleveland; Melana Yuzefpolskaya; Christopher T Salerno; Mary N Walsh; Carmelo A Milano; Chetan B Patel; Steven W Hutchins; John Ransom; Gregory A Ewald; Akinobu Itoh; Nirav Y Raval; Scott C Silvestry; Rebecca Cogswell; Ranjit John; Arvind Bhimaraj; Brian A Bruckner; Brian D Lowes; John Y Um; Valluvan Jeevanandam; Gabriel Sayer; Abeel A Mangi; Ezequiel J Molina; Farooq Sheikh; Keith Aaronson; Francis D Pagani; William G Cotts; Antone J Tatooles; Ashok Babu; Don Chomsky; Jason N Katz; Paul B Tessmann; David Dean; Arun Krishnamoorthy; Joyce Chuang; Ia Topuria; Poornima Sood; Daniel J Goldstein Journal: N Engl J Med Date: 2019-03-17 Impact factor: 91.245
Authors: James K Kirklin; David C Naftel; Robert L Kormos; Francis D Pagani; Susan L Myers; Lynne W Stevenson; Michael A Acker; Daniel L Goldstein; Scott C Silvestry; Carmelo A Milano; J T Baldwin; J Timothy Baldwin; Sean Pinney; J Eduardo Rame; Marissa A Miller Journal: J Heart Lung Transplant Date: 2013-11-27 Impact factor: 10.247
Authors: James K Kirklin; Francis D Pagani; Robert L Kormos; Lynne W Stevenson; Elizabeth D Blume; Susan L Myers; Marissa A Miller; J Timothy Baldwin; James B Young; David C Naftel Journal: J Heart Lung Transplant Date: 2017-07-15 Impact factor: 10.247
Authors: Jasmin S Hanke; Sebastian V Rojas; Günes Dogan; Christina Feldmann; Erik Beckmann; Ezin Deniz; Bettina Wiegmann; Jana-Elena Michaelis; L Christian Napp; Dominik Berliner; Malakh Shrestha; Johann Bauersachs; Axel Haverich; Jan D Schmitto Journal: Eur J Cardiothorac Surg Date: 2017-05-01 Impact factor: 4.191
Authors: Randall C Starling; Nader Moazami; Scott C Silvestry; Gregory Ewald; Joseph G Rogers; Carmelo A Milano; J Eduardo Rame; Michael A Acker; Eugene H Blackstone; John Ehrlinger; Lucy Thuita; Maria M Mountis; Edward G Soltesz; Bruce W Lytle; Nicholas G Smedira Journal: N Engl J Med Date: 2013-11-27 Impact factor: 91.245
Authors: Matthew A Schechter; Chetan B Patel; Laura J Blue; Ian Welsby; Joseph G Rogers; Jacob N Schroder; Carmelo A Milano Journal: Ann Thorac Surg Date: 2014-12-10 Impact factor: 4.330
Authors: Jasmin S Hanke; Günes Dogan; Leonard Wert; Marcel Ricklefs; Jan Heimeshoff; Anamika Chatterjee; Christina Feldmann; Axel Haverich; Jan D Schmitto Journal: J Thorac Dis Date: 2018-06 Impact factor: 2.895
Authors: Hideki Tsubota; Roberto V P Ribeiro; Filio Billia; Robert J Cusimano; Terrence M Yau; Mitesh V Badiwala; William E Stansfield; Vivek Rao Journal: Can J Surg Date: 2017-08 Impact factor: 2.089
Authors: Davor Milicic; Binyamin Ben Avraham; Ovidiu Chioncel; Yaron D Barac; Eva Goncalvesova; Avishai Grupper; Johann Altenberger; Maria Frigeiro; Arsen Ristic; Nicolaas De Jonge; Steven Tsui; Jacob Lavee; Giuseppe Rosano; Marisa Generosa Crespo-Leiro; Andrew J S Coats; Petar Seferovic; Frank Ruschitzka; Marco Metra; Stefan Anker; Gerasimos Filippatos; Stamatis Adamopoulos; Miriam Abuhazira; Jeremy Elliston; Israel Gotsman; Righab Hamdan; Yoav Hammer; Tal Hasin; Lorrena Hill; Osnat Itzhaki Ben Zadok; Wilfried Mullens; Sanemn Nalbantgil; Massimo Francesco Piepoli; Piotr Ponikowski; Luciano Potena; Arjang Ruhparwar; Aviv Shaul; Laurens F Tops; Stephan Winnik; Tiny Jaarsma; Finn Gustafsson; Tuvia Ben Gal Journal: ESC Heart Fail Date: 2021-09-14
Authors: Zak Loring; Sounok Sen; Eric Black-Maier; Brett D Atwater; Stuart D Russell; Adam D DeVore; Jonathan P Piccini Journal: J Am Heart Assoc Date: 2020-08-13 Impact factor: 5.501